2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160093
    SQLE-IN-1 1019169-83-5 98.15%
    SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT.
    SQLE-IN-1
  • HY-18101A
    BD1063 dhydrochloride 206996-13-6 ≥98.0%
    BD1063 dhydrochloride is a potent and selective sigma 1 receptor antagonist.
    BD1063 dhydrochloride
  • HY-B0281A
    Ranitidine hydrochloride 66357-59-3 ≥98.0%
    Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice.
    Ranitidine hydrochloride
  • HY-N1428S
    Citric acid-d4 147664-83-3 ≥98.0%
    Citric acid-d4 is the deuterium labeled Citric acid (HY-N1428). Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Citric acid-d4
  • HY-113149A
    Argininosuccinic acid disodium 918149-29-8
    Argininosuccinic acid disodium is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid disodium can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid disodium can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid disodium can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc.
    Argininosuccinic acid disodium
  • HY-113920A
    Azumolene 64748-79-4 99.11%
    Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. Azumolene is a ryanodine receptor (RyR) modulator and inhibits the calcium-release through ryanodine receptor. Azumolene can be used for malignant hyperthermia research.
    Azumolene
  • HY-128851B
    Coenzyme A sodium 55672-92-9 99.46%
    Coenzyme A (CoASH) sodium is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
    Coenzyme A sodium
  • HY-N0229S3
    L-Alanine-d4 18806-29-6 ≥99.0%
    L-Alanine-d4 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-d4
  • HY-N0420S1
    Succinic-2,2,3,3-d4 acid 14493-42-6 ≥99.0%
    Succinic-2,2,3,3-d4 acid is the deuterium labeled Succinic acid. Succinic acid is an intermediate product of the tricarboxylic acid cycle, as well as one of fermentation products of anaerobic metabolism.
    Succinic-2,2,3,3-d4 acid
  • HY-N0623S2
    L-Tryptophan-13C11 202114-65-6 99.60%
    L-Tryptophan-13C11 is the 13C-labeled L-Tryptophan. L-Tryptophan (Tryptophan) is an essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3.
    L-Tryptophan-13C11
  • HY-W005629
    Leelamine 1446-61-3 ≥98.0%
    Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells.
    Leelamine
  • HY-W007347
    1,2-Cyclohexanedione 765-87-7 ≥98.0%
    1,2-Cyclohexanedione is an endogenous metabolite.
    1,2-Cyclohexanedione
  • HY-W012926
    Dihydrouracil 504-07-4
    Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient.
    Dihydrouracil
  • HY-14657
    Dantrolene sodium 14663-23-1 ≥98.0%
    Dantrolene sodium is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium is also a calcium channel protein inhibitor. Dantrolene sodium inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties.
    Dantrolene sodium
  • HY-113159
    Docosapentaenoic acid (22n-3) 24880-45-3 ≥98.0%
    Docosapentaenoic acid (22n-3) is a component of phospholipids. Docosapentaenoic acid 22n-3 has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 increases cell vitality. Docosapentaenoic acid 22n-3 has a weak anti-inflammatory effect.
    Docosapentaenoic acid (22n-3)
  • HY-115062
    MJ33 lithium salt 1007476-63-2 ≥99.0%
    MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.
    MJ33 lithium salt
  • HY-13012G
    RepSox (GMP) 446859-33-2 98%
    RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor.
    RepSox (GMP)
  • HY-100775
    Fezagepras sodium 1254472-97-3 99.78%
    Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
    Fezagepras sodium
  • HY-124622
    NNC-0640 307986-98-7 98.43%
    NNC-0640 is an effective negative allosteric modulator (NAM) of the human glucagon receptor (GCGR), with an IC50 value of 69.2 nM. NNC-0640 holds potential for research in the field of diabetes.
    NNC-0640
  • HY-142162
    LSN3318839 2764704-18-7 99.81%
    LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar.
    LSN3318839
Cat. No. Product Name / Synonyms Application Reactivity